Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 885Precursor Cell Lymphoblastic Leukemia-Lymphoma 511Hematologic Neoplasms 466Leukemia, Lymphocytic, Chronic, B-Cell 392Leukemia 337Myelodysplastic Syndromes 330Lymphoma 208Lymphoma, Non-Hodgkin 191Multiple Myeloma 146Leukemia, Myelogenous, Chronic, BCR-ABL Positive 142Recurrence 138Neoplasms 135Leukemia, Myelomonocytic, Chronic 112Burkitt Lymphoma 93Lymphoma, Mantle-Cell 92Lymphoma, Follicular 92Lymphoma, Large B-Cell, Diffuse 91Myeloproliferative Disorders 84Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 83Leukemia, Biphenotypic, Acute 81Lymphoma, B-Cell, Marginal Zone 75Hodgkin Disease 72Lymphoma, B-Cell 64Waldenstrom Macroglobulinemia 54Primary Myelofibrosis 54Leukemia, B-Cell 52Anemia, Refractory, with Excess of Blasts 46Leukemia, Myeloid, Chronic-Phase 41Hematologic Diseases 37Lymphoma, T-Cell 33

Interventions

rasburicase 1Uric Acid 1Urate Oxidase 1Pegloticase 1Oxidoreductases 1Carbamates 1Amides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Tumor Lysis Syndrome × Other hematologic neoplasm × 1 year × Clear all
NCT04745910 2026-05-06

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 4 Completed
10 enrolled
Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡